Cargando…

A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients

We evaluated a cocktail of HLA-A2-specific peptides including heteroclitic XBP1 US(184-192) (YISPWILAV), heteroclitic XBP1 SP(367-375) (YLFPQLISV), native CD138(260-268) (GLVGLIFAV) and native CS1(239-247) (SLFVLGLFL), for their ability to elicit multipeptide specific cytotoxic T lymphocytes (MP-CTL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bae, Jooeun, Prabhala, Rao, Voskertchian, Annie, Brown, Andrew, Maguire, Craig, Richardson, Paul, Dranoff, Glen, Anderson, Kenneth C., Munshi, Nikhil C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237716/ https://www.ncbi.nlm.nih.gov/pubmed/24935722 http://dx.doi.org/10.1038/leu.2014.159

Ejemplares similares

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2011)

Smoldering Multiple Myeloma
por: Gao, Minjie, et al.
Publicado: (2015)

Genomic patterns of progression in smoldering multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2018)

Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3(+)CD8(+) T cells against Various Solid Tumors
por: Bae, Jooeun, et al.
Publicado: (2015)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis
por: Carrasco, Daniel R., et al.
Publicado: (2007)

Recent Advances in the Management of Smoldering Multiple Myeloma
por: Madhira, Bhaskara Reddy, et al.
Publicado: (2020)

Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
por: Markus, Efrat, et al.
Publicado: (2020)

Smoldering Multiple Myeloma Arising in Ulcerative Colitis
por: Yang, Xue, et al.
Publicado: (2018)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

How We Approach Smoldering Multiple Myeloma
por: Raje, Noopur, et al.
Publicado: (2020)

Systemic Mastocytosis Associated with “Smoldering” Multiple Myeloma
por: Zanelli, Magda, et al.
Publicado: (2021)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

Risk Stratification and Treatment in Smoldering Multiple Myeloma
por: Lussier, Tyler, et al.
Publicado: (2021)

How I approach smoldering multiple myeloma
por: Vaxman, Iuliana, et al.
Publicado: (2022)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2021)

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
por: Kim, E. Bridget, et al.
Publicado: (2020)

Amyloid arthropathy in smoldering myeloma: Do not take it lightly
por: Muchtar, Eli, et al.
Publicado: (2021)

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Kidney transplantation for active multiple myeloma or smoldering myeloma: a case–control study
por: Kormann, Raphaël, et al.
Publicado: (2019)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

PB2077: COMPARISON OF PLASMA CELL PERCENTAGE BY BONE MARROW ASPIRATE MORPHOLOGY AND CD138-STAINED BONE MARROW BIOPSY IN SMOLDERING MYELOMA TO PREDICT TRANSFORMATION TO SYMPTOMATIC MYELOMA
por: Cashman, Helen, et al.
Publicado: (2023)

Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
por: Lionetti, Marta, et al.
Publicado: (2021)

Prevalence, incidence and survival of smoldering multiple myeloma in the United States
por: Ravindran, A, et al.
Publicado: (2016)

Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case
por: Ghanem, Sassine, et al.
Publicado: (2016)

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Smoldering multiple myeloma revealed by superior ophthalmic vein thrombosis
por: Bouattour, Nadia, et al.
Publicado: (2020)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
por: Visram, A., et al.
Publicado: (2021)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2013)

PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients
por: Costa, Federica, et al.
Publicado: (2021)

Smoldering myeloma presenting as progressive multifocal leukoencephalopathy: a case report
por: Troppmann, Martina, et al.
Publicado: (2012)

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
por: Blum, Agnieszka, et al.
Publicado: (2018)

Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma
por: Manzoni, Martina, et al.
Publicado: (2020)

Eosinophilic Fasciitis and Smoldering Multiple Myeloma: An Exceptional Association in Young Adults
por: Jabbouri, Rajaa, et al.
Publicado: (2022)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
por: Mohyuddin, Ghulam Rehman, et al.
Publicado: (2023)

Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma
por: Prabhala, Rao H., et al.
Publicado: (2015)

Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_tarsdnshgn5psfi6iepcugflmi